DrugPatentWatch Database Preview

Details for Patent: 8,415,335

Which drugs does patent 8,415,335 protect, and when does it expire?

Patent 8,415,335 protects VASCEPA and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 8,415,335

Title:	Methods of treating hypertriglyceridemia
Abstract:	In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Inventor(s):	Manku; Mehar (England, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceutical Ireland Limited (Dublin, IE)
Application Number:	13/349,157
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,415,335
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,415,335

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA	➤ Sign Up
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017		RX	Yes	No	➤ Sign Up	➤ Sign Up				METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,415,335

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,318,715	Methods of treating hypertriglyceridemia	➤ Sign Up
8,546,372	Methods of treating hypertriglyceridemia	➤ Sign Up
8,357,677	Methods of treating hypertriglyceridemia	➤ Sign Up
8,367,652	Methods of treating hypertriglyceridemia	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,415,335

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010213899	➤ Sign Up
Canada	2751576	➤ Sign Up
Cyprus	1114276	➤ Sign Up
Denmark	2395991	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,415,335

For more information try a trial or see the plans and pricing